Related Experiment Video
Updated: Sep 11, 2025

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections
Ahmed Elfadadny1,2, Rokaia F Ragab1,3, Osama Aldesoky Abd Alaziz4
1Laboratory of Internal Medicine, Cooperative Division of Veterinary Sciences, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Japan.
Abstract:
The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa infections poses a major challenge in clinical settings, particularly when antibiotic therapy fails and surgical source control is not feasible. Bacteriophage therapy (BT) has emerged as a promising alternative, offering a targeted approach to combat persistent infections. Recent advancements in phage isolation, purification and genomic characterization have facilitated their use in compassionate treatment cases. Studies suggest that phage-antibiotic synergy can enhance bacterial eradication while potentially mitigating resistance development. However, challenges remain regarding optimal dosing strategies, host immune responses and regulatory approval pathways. This review examines the current state of BT for P. aeruginosa infections, its mechanisms of action, clinical applications and future directions for integrating phage-based treatments into infectious disease management.
Insights
Multidrug-resistant Pseudomonas aeruginosa infections are a growing problem. Bacteriophage therapy offers a targeted alternative, showing promise in combination with antibiotics for better eradication and reduced resistance.
Area of Science:
- Microbiology
- Infectious Diseases
- Bacteriophage Therapy
Background:
- Rising incidence of multidrug-resistant (MDR) Pseudomonas aeruginosa infections presents significant clinical challenges.
- Treatment failure with antibiotics and limitations in surgical intervention necessitate alternative therapeutic strategies.
Purpose of the Study:
- To review the current status of bacteriophage therapy (BT) for P. aeruginosa infections.
- To explore the mechanisms of action, clinical applications, and future prospects of BT.
Main Methods:
- Review of recent advancements in phage isolation, purification, and genomic characterization.
- Analysis of studies on phage-antibiotic synergy and clinical compassionate use cases.
Main Results:
- Bacteriophage therapy is a promising alternative for MDR P. aeruginosa infections.
- Phage-antibiotic synergy may enhance bacterial eradication and mitigate resistance development.
Conclusions:
- BT offers a targeted approach to combat persistent P. aeruginosa infections.
- Challenges include optimizing dosing, understanding host immune responses, and navigating regulatory pathways.
More Related Videos
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
08:46Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
Published on: January 26, 2024
Related Concept Videos
Lytic Cycle of Bacteriophages
Gene Regulation in Microbial Communities: Quorum Sensing
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
DNA Bacteriophages
Lysogenic Cycle of Bacteriophages